|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
60.950 -0.800 (-1.296%) | 2026/06 - Interim RMB(K¥) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 370,252 | 211,248 | (76,646) | (303,266) |
| Net Cash from / (used in) Investing Activities | -- | (184,858) | (137,115) | (100,278) | (153,738) |
| Net Cash from / (used in) Financing Activities | -- | 979,860 | (92,029) | (37,819) | 587,200 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 1,165,254 | (17,896) | (214,743) | 130,196 |
| Cash & Cash Equivalents at beginning of period | -- | 384,458 | 399,607 | 610,882 | 466,445 |
| Effect of Foreign Exchange Rate Changes | -- | 2,844 | 2,747 | 3,468 | 14,241 |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 1,552,556 | 384,458 | 399,607 | 610,882 |
| Remarks: | Real time quote last updated: 09/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 241,095 |
| %Change | 402.292% |
| EPS / (LPS) | RMB 0.540 |
| NBV Per Share (¥) | RMB 5.419 |